Drug intelligence / Profile preview

P54

Development stage: Preclinical
Lead developer: Phytopharm
Modality: Small Molecules

Overview

P54 is an investigational small molecule drug that acts as an anti-inflammatory agent. Its primary mechanism of action is the inhibition of the induction of the enzyme nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), specifically targeting the NF-kappa-B p100 and p105 subunits. By inhibiting NFkB, P54 suppresses downstream inflammatory genes such as cyclooxygenase-2 (COX II) and inducible nitric oxide synthase (iNOS). This results in reduced inflammation associated with conditions like cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis[1].

Targets

NFKB1 (NF-κB1)NFKB2 (NF-κB2)

Beyond the preview

Go deeper on P54.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P54.

Explore the full profile